Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kwality Pharma Gains Greece Approval for Leuprorelin Acetate Injectable Suspension
Details : Luprodex (leuprorelin acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer.
Brand Name : Luprodex
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?